Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma

被引：0
作者：
Lidia Gil
Maciej Kazmierczak
Renata Kroll-Balcerzak
Mieczyslaw Komarnicki
机构：
[1] Poznan University of Medical Sciences,Department of Haematology and Bone Marrow Transplantation
来源：
Medical Oncology | 2014年 / 31卷
关键词：
Bendamustine; First-line treatment; Non-Hodgkin lymphoma; Indolent lymphoma; Mantle cell lymphoma; Aggressive lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL) with emphasis on efficacy and toxicity are presented. Furthermore, completed and ongoing clinical trials evaluating upfront bendamustine effectiveness in combination with other agents are discussed. The review refers mainly to indolent lymphoma, mantle cell lymphoma and aggressive lymphoma, as the most commonly diagnosed NHL types. Finally, we elaborated on the safety profile of bendamustine and the perspectives of using the drug as a first-line therapy.
引用
收藏
相关论文
共 197 条
[1]  
Leoni LM(2008)Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 309-317
[2]  
Bailey B(2002)Metabolism and mechanisms of action of bendamustine: rationales for combination therapies Semin Oncol 29 4-11
[3]  
Reifert J(2001)In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine Haematologica 86 485-493
[4]  
Bendall HH(2010)Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study Cancer 116 106-114
[5]  
Zeller RW(2008)Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 204-210
[6]  
Corbeil J(2008)Chemotherapy combinations with monoclonal antibodies in non-Hodgkin’s lymphoma Semin Hematol 45 90-94
[7]  
Elliott G(2006)Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19) J Cancer Res Clin Oncol 132 105-112
[8]  
Niemeyer CC(2013)Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet 381 1203-1210
[9]  
Gandhi V(2013)Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes Expert Rev Hematol 6 525-537
[10]  
Chow KU(2012)Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with waldenstrom macroglobulinemia: results from prospective, randomized, multicenter study (StiL NHL 7-2008—MAINTAIN) Blood 120 2739-1449
12345678910